

# Martin J Edelman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4192343/martin-j-edelman-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19  
papers

509  
citations

7  
h-index

22  
g-index

24  
ext. papers

691  
ext. citations

4.7  
avg, IF

3.28  
L-index

#	Paper	IF	Citations
19	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102337	14.4	0
18	Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). <i>Oncogenesis</i> , <b>2021</b> , 10, 29	6.6	3
17	Benchmarks for Academic Oncology Faculty. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e440-e444	2.3	
16	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 54-65	8.9	6
15	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 66-75	8.9	7
14	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> ,	4	6
13	Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1137-1146	8.9	22
12	The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 38-45	4	2
11	Biomarker Testing in Lung Cancer-What Does It Mean?. <i>JAMA Network Open</i> , <b>2020</b> , 3, e207171	10.4	0
10	Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e130-e141	4.9	5
9	Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 827-835	3.9	2
8	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , <b>2019</b> , 36, 2638-2678	4.1	86
7	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. <i>Cancer</i> , <b>2019</b> , 125, 382-390	6.4	9
6	Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e107-e114	4.9	9
5	Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 445-452	4	6
4	Daily diary study of hope, stigma, and functioning in lung cancer patients. <i>Health Psychology</i> , <b>2018</b> , 37, 218-227	5	16
3	Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1263-1266	13.4	148

2	Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2017</b> , 114, 44-49	5.9	6
1	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1475-84	10.3	174